CN112334471A - 具有药物活性的吡唑并-三嗪和/或吡唑并-嘧啶衍生物 - Google Patents

具有药物活性的吡唑并-三嗪和/或吡唑并-嘧啶衍生物 Download PDF

Info

Publication number
CN112334471A
CN112334471A CN201980039675.8A CN201980039675A CN112334471A CN 112334471 A CN112334471 A CN 112334471A CN 201980039675 A CN201980039675 A CN 201980039675A CN 112334471 A CN112334471 A CN 112334471A
Authority
CN
China
Prior art keywords
independently
compound
occurrence
cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980039675.8A
Other languages
English (en)
Chinese (zh)
Inventor
南基然
金在昇
田義珍
兪東勳
徐武永
朴桐湜
J.艾克霍夫
G·齐施因斯基
乌维·科赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lead Discovery Center GmbH
Qurient Co Ltd
Original Assignee
Lead Discovery Center GmbH
Qurient Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center GmbH, Qurient Co Ltd filed Critical Lead Discovery Center GmbH
Publication of CN112334471A publication Critical patent/CN112334471A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980039675.8A 2018-04-11 2019-04-11 具有药物活性的吡唑并-三嗪和/或吡唑并-嘧啶衍生物 Pending CN112334471A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656041P 2018-04-11 2018-04-11
US62/656,041 2018-04-11
PCT/EP2019/059289 WO2019197546A1 (en) 2018-04-11 2019-04-11 Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
CN112334471A true CN112334471A (zh) 2021-02-05

Family

ID=66334384

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980039675.8A Pending CN112334471A (zh) 2018-04-11 2019-04-11 具有药物活性的吡唑并-三嗪和/或吡唑并-嘧啶衍生物

Country Status (14)

Country Link
US (1) US11858937B2 (enExample)
EP (1) EP3774809A1 (enExample)
JP (2) JP7406501B2 (enExample)
KR (1) KR102966358B1 (enExample)
CN (1) CN112334471A (enExample)
AU (1) AU2019250504B2 (enExample)
BR (1) BR112020020645A2 (enExample)
CA (1) CA3095426A1 (enExample)
IL (2) IL299105B2 (enExample)
MX (1) MX2020010563A (enExample)
MY (1) MY207194A (enExample)
PH (1) PH12020551638A1 (enExample)
SG (1) SG11202009466UA (enExample)
WO (1) WO2019197546A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024174949A1 (zh) * 2023-02-20 2024-08-29 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN119606955A (zh) * 2024-11-13 2025-03-14 南方医科大学 Txd-174在制备治疗和/或预防黄病毒属病毒感染产品中的应用
WO2025162425A1 (zh) * 2024-02-01 2025-08-07 广州费米子科技有限责任公司 吡唑并嘧啶化合物作为tyk2抑制剂

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
EP4255909A1 (en) * 2020-12-02 2023-10-11 Qurient Co. Ltd. Compounds having cyclin-dependent kinase(cdk)-inhibitory function
WO2022248682A1 (en) * 2021-05-28 2022-12-01 Qurient Co., Ltd. Compounds for degradation of cyclin-dependent kinase 7 (cdk7)
US20250042903A1 (en) * 2021-06-17 2025-02-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Triazine inhibitors of cyclin-dependent kinases
WO2023175173A1 (en) * 2022-03-18 2023-09-21 Qurient Co., Ltd. Cdk7 inhibitors for antiviral treatment
US20260041693A1 (en) 2022-08-05 2026-02-12 Qurient Co., Ltd. Combination therapy of cdk7 inhibitors with other anti-cancer therapies
KR20240095030A (ko) 2022-12-15 2024-06-25 부산대학교 산학협력단 간과 신장의 염증 및 섬유화 치료 효과가 있는 신규 트리아진 유도체 및 이의 제조방법
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025040170A1 (zh) * 2023-08-24 2025-02-27 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104350054A (zh) * 2012-03-01 2015-02-11 利德探索中心有限公司 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并-三嗪衍生物
WO2015154022A1 (en) * 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107530329A (zh) * 2015-03-09 2018-01-02 奥瑞基尼探索技术有限公司 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
JP2010529140A (ja) * 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2019035866A1 (en) 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104350054A (zh) * 2012-03-01 2015-02-11 利德探索中心有限公司 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并-三嗪衍生物
WO2015154022A1 (en) * 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107530329A (zh) * 2015-03-09 2018-01-02 奥瑞基尼探索技术有限公司 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024174949A1 (zh) * 2023-02-20 2024-08-29 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
WO2025162425A1 (zh) * 2024-02-01 2025-08-07 广州费米子科技有限责任公司 吡唑并嘧啶化合物作为tyk2抑制剂
CN119606955A (zh) * 2024-11-13 2025-03-14 南方医科大学 Txd-174在制备治疗和/或预防黄病毒属病毒感染产品中的应用

Also Published As

Publication number Publication date
BR112020020645A2 (pt) 2021-01-12
SG11202009466UA (en) 2020-10-29
CA3095426A1 (en) 2019-10-17
AU2019250504B2 (en) 2023-05-18
JP2023138859A (ja) 2023-10-02
IL299105B2 (en) 2024-02-01
KR102966358B1 (ko) 2026-05-15
JP2021521129A (ja) 2021-08-26
WO2019197546A1 (en) 2019-10-17
KR20200143429A (ko) 2020-12-23
MX2020010563A (es) 2020-10-22
US20210139483A1 (en) 2021-05-13
IL299105B1 (en) 2023-10-01
US11858937B2 (en) 2024-01-02
PH12020551638A1 (en) 2021-07-26
IL277694A (en) 2020-11-30
JP7406501B2 (ja) 2023-12-27
EP3774809A1 (en) 2021-02-17
MY207194A (en) 2025-02-05
AU2019250504A1 (en) 2020-10-15
NZ768400A (en) 2024-07-05
IL299105A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
KR102966358B1 (ko) 약학적으로 유효한 피라졸로-트리아진 및/또는 피라졸로-피리미딘 유도체
CN112142735B (zh) 一类稠和氰基吡啶类化合物、制备方法和用途
KR102966455B1 (ko) 사이클린 의존성 키나아제의 선택적 억제제로서의 피라졸로-트리아진 및/또는 피라졸로피리미딘 유도체
CN102482219B (zh) 吡喃酮和吡啶酮衍生物的制备方法
CN106029659B (zh) 谷氨酰胺酶抑制剂
JP6959248B2 (ja) 癌治療用の４，６−ジヒドロピロロ［３，４−ｃ］ピラゾール−５（１Ｈ）−カルボニトリル誘導体
CN112300173A (zh) 一类含氮多环类化合物、制备方法和用途
CN110191887B (zh) IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
BR112014021189B1 (pt) Composto, seu uso para a preparação de uma composição farmacêutica, e, composição farmacêutica contendo o mesmo
US12606561B2 (en) Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors
WO2002002550A1 (en) Novel pyrazinone derivatives
US20240343732A1 (en) Compounds for degradation of cyclin-dependent kinase 7(cdk7)
RU2818563C2 (ru) Фармацевтически активные производные пиразолотриазина и/или пиразолопиримидина
CN111763217A (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
RU2809779C2 (ru) Производные пиразолотриазина и/или пиразолопиримидина в качестве селективного ингибитора циклинзависимой киназы
HK40082693B (en) 8-oxo-3-azabicyclo[3.2.1]octane compounds or salts thereof, and preparation method and use thereof
HK40082693A (en) 8-oxo-3-azabicyclo[3.2.1]octane compounds or salts thereof, and preparation method and use thereof
WO2023137634A1 (zh) 三并环化合物、其制备、药物组合物及应用
CN120303269A (zh) 用于调节hur(elavl1)的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination